Effect of Zinc Gluconate Supplementation on C-Reactive Protein and Malondialdehyde in Patients with Behcet's Disease: A Double-Blind Randomized Controlled Clinical Trial

Amir Hossein  Faghfouri; Seyyed Morteza  Seyyed Shoura; Ghazaleh  shahhosseini; Amir Arshia  Khodabandehloo; Pourya  Fathollahia; Alireza  Khabbazi; Vali  Musazadeh; Beitullah  Alipour

doi:10.18502/jnfs.v10i2.18530

Amir Hossein Faghfouri Maternal and Childhood Obesity Research Center, Urmia University of Medical Sciences, Urmia, Iran
Seyyed Morteza Seyyed Shoura Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
Ghazaleh shahhosseini Department of Dentistry, Islamic Azad university, Tehran, Iran
Amir Arshia Khodabandehloo Department of Converging Sciences and Technologies, Islamic Azad University Science and Research Branch ,Tehran, Iran
Pourya Fathollahia Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
Alireza Khabbazi Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;
Vali Musazadeh Student research committee, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
Beitullah Alipour Department of Community Nutrition, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

DOI: https://doi.org/10.18502/jnfs.v10i2.18530

Keywords: Malondialdehyde; Zinc; CRP; Behcet disease

Abstract

Background: Behçet's disease (BD) with autoimmune and auto-inflammatory nature is more prevalent in Silk Road countries. The current study aimed to investigate the effect of zinc gluconate supplementation on C-reactive protein (CRP) and malondialdehyde (MDA) levels in BD patients. Methods: This randomized controlled clinical trial was conducted on 50 Iranian BD patients. Participants were randomly assigned into either placebo or zinc gluconate (30 mg/day) groups for 12 weeks. Before and after the intervention, serum MDA and CRP levels were measured. Results: Zinc supplementation led to a significant increase in serum zinc levels compared to the placebo group (P<0.05). There was no significant difference in MDA serum levels between the groups after adjusting for the baseline values and confounding factors (P>0.05). Zinc supplementation led to a significant improvement in CRP serum levels compared to the placebo group following adjustment for the effect of baseline values and confounding factors (P=0.012 and 0.04, respectively). Conclusion: Zinc supplementation in an elemental dose of 30 mg per day has an anti-inflammatory effect in BD patients by reducing CRP levels. The beneficial effect of zinc on lipid peroxidation in BD patients was not shown in the study.